A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non–small-cell lung cancer (AK104-202 study)
- Resource Type
- Article
- Source
- In
Lung Cancer October 2023 184 - Subject
- Language
- ISSN
- 0169-5002